SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Maksymowych WP. Ankylosing spondylitis: pathology, etiology and pathogenesis. In: HochbergMC, SilmanAJ, SmolenJS, WeinblattME, WeismanMH, editors. Rheumatology. 4th ed. New York: Mosby, Harcourt Health Sciences; 2008. p. 111530.
  • 2
    Eulderink F. Pathology of ankylosing spondylitis. Spine State of the Art Reviews 1990; 4: 50728.
  • 3
    Van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008; 58: 132431.
  • 4
    Van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, et al, and the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008; 58: 306370.
  • 5
    Maksymowych WP, Lambert RG. Magnetic resonance imaging for spondyloarthritis—avoiding the minefield [editorial]. J Rheumatol 2007; 34: 25965.
  • 6
    Bollow M, Fischer T, Reisshauer H, Backhaus M, Sieper J, Hamm B, et al. Quantitative analyses of sacroiliac biopsies in spondylarthropathies: T cells and macrophages predominate in early and active sacroiliitis—cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000; 59: 13540.
  • 7
    Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003; 48: 112636.
  • 8
    Maksymowych WP, Inman RD, Salonen D, Dhillon SS, Krishnananthan R, Stone M, et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. Arthritis Rheum 2005; 53: 5029.
  • 9
    Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford) 2005; 44: 152530.
  • 10
    Lambert RG, Salonen D, Rahman P, Inman RD, Wong RL, Einstein SG, et al, for the M03-606 Study Group. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2007; 56: 400514.
  • 11
    Braun J, Baraliakos X, Golder W, Hermann KG, Listing J, Brandt J, et al. Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis 2004; 63: 104655.
  • 12
    Creemers MC, Franssen MJ, van 't Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005; 64: 1279.
  • 13
    Wanders AJ, Landewe RB, Spoorenberg A, Dougados M, van der Linden S, Mielants H, et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis Rheum 2004; 50: 262232.
  • 14
    Van der Heijde DM, Wanders A, Mielants H, Dougados M, Landewe RB. Prediction of progression of radiographic damage over 4-years in patients with ankylosing spondylitis [abstract]. Ann Rheum Dis 2004; 63: OP132.
  • 15
    Maksymowych WP, Landewe R, Conner-Spady B, Dougados M, Mielants H, van der Tempel H, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007; 56: 184653.
  • 16
    Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 2007; 66: 9105.
  • 17
    Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 3618.
  • 18
    Maksymowych WP, Salonen D, Inman RD, Paul FL, Lambert RG. CANaDian evaluation of Low DosE infliximab in ankylosing spondylitis (CANDLE)-12 week magnetic resonance imaging evaluation of spinal inflammation with the SPARCC MRI method [abstract]. Arthritis Rheum 2007; 56 Suppl 9: S473.
  • 19
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 228691.
  • 20
    Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 22815.
  • 21
    Maksymowych WP, Pedersen SJ, Ostergaard M, Chiowchanwisawakit P, Conner-Spady B, Lambert RG. Re-appraisal of the chronic MRI changes in AS by the Canada/Denmark MRI Working Group: validation of the post-inflammatory fat signal [abstract]. Ann Rheum Dis 2008; 67: SAT0249.
  • 22
    Appel H, Loddenkemper C, Grozdanovic Z, Ebhardt H, Dreimann M, Hempfing A, et al. Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther 2006; 8: R143.
  • 23
    Anandarajah AP, Schwarz EM, Totterman S, Monu J, Feng CY, Shao T, et al. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis 2008; 67: 296301.
  • 24
    Romagnani S. Human Th17 cells [review]. Arthritis Res Ther 2008; 10: 206.
  • 25
    Wendling D, Racadot E, Cedoz JP, Dumoulin G. IL-17, BMP-7 and bone remodelling in ankylosing spondylitis [abstract]. Arthritis Rheum 2006; 54 Suppl 9: S716.
  • 26
    Re F, Strominger JL. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 2001; 276: 376929.
  • 27
    Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007; 13: 15663.
  • 28
    Lories RJ, Luyten FP. Bone morphogenetic proteins in destructive and remodeling arthritis. Arthritis Res Ther 2007; 9: 20715.
  • 29
    Lories RJ, Derese I, de Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007; 56: 48997.
  • 30
    De Vlam K, Mielants H, Verstaete KL, Veys EM. The zygapophyseal joint determines morphology of the enthesophyte. J Rheumatol 2000; 27: 17329.